News & Updates

Show Multimedia Only
Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF

Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF

19 Feb 2022

Patients with nonvalvular atrial fibrillation (NVAF) and acute heart failure (AHF) see elevated levels of D-dimer, for which edoxaban may be effective, reports a recent study.

19 Feb 2022
Stroke risk elevated first 3 days post–COVID-19 diagnosis

Stroke risk elevated first 3 days post–COVID-19 diagnosis

18 Feb 2022 byRoshini Claire Anthony

Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.

18 Feb 2022
Ixazomib dexamethasone a new treatment in the arsenal against RRMM

Ixazomib dexamethasone a new treatment in the arsenal against RRMM

18 Feb 2022

In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.

18 Feb 2022
Being physically active helps prevent NAFLD

Being physically active helps prevent NAFLD

18 Feb 2022 byStephen Padilla

Physical activity (PA) is associated with a lower prevalence of nonalcoholic fatty liver disease (NAFLD), with greater benefits for higher PA intensities, reveals a study. Better metabolic health, particularly lower waist circumference and insulin resistance, mediates this association.

18 Feb 2022